You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    Assays for accurate diagnosis of early stages of infection with biothreat agents, on the day of infection or within a few days of infection, will find wide use in both civilian and military applications These diagnostic assays, which are anticipated to be highly specific and sensitive, will add to the repertoire of tools of hospitals and clinics that serve our armed forces personnel deployed on th ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  2. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  3. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terrible morbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditional vaccines have contributed greatly to public health, they have some limitations especially in the context of operati ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  4. MK III Upper Extremity Exoskeleton

    SBC: Ekso Bionics Inc            Topic: 739552

    As the carry and protective gear of the modern war fighter increases, the burden on the human body will necessarily increase. In our present TALOS MkIII project, we are developing lower body augmentation to preserve speed and agility while bearing this weight. Yet we cannot ignore the impact of this weight on the upper body: in this project we propose to develop an upper body exoskeleton with p ...

    STTR Phase II 2015 Department of DefenseSpecial Operations Command
  5. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD RESEARCH CORPORATION            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens, whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial and alphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable an ...

    STTR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government